Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED].
Goodin
D S
DS
Frohman
E M
EM
Garmany
G P
GP
Halper
J
J
Likosky
W H
WH
Lublin
F D
FD
Silberberg
D H
DH
Stuart
W H
WH
van den Noort
S
S
D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D000068717:Glatiramer Acetate; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use*; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use; D010951:Plasma Exchange; D016896:Treatment Outcome
D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone